您的位置: 首页 > 农业专利 > 详情页

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
专利权人:
SAVIENT PHARMACEUTICALS INC.
发明人:
ROSARIO-JANSEN THERESA,WRIGHT DAVID ERICK
申请号:
NZ59708910
公开号:
NZ597089A
申请日:
2010.06.25
申请国别(地区):
NZ
年份:
2014
代理人:
摘要:
597089 Disclosed is a method for diagnosing the risk of infusion reactions in a patient undergoing PEGylated uricase therapy, comprising the steps of: determining uric acid levels in a biological sample obtained from said patient at least 2 hours after administration of PEGylated uricase, wherein a uric acid level of more than 4mg/dl indicates that said patient is at risk of infusion reactions and PEGylated uricase therapy is to be discontinued. Further disclosed is a method to predict whether a patient will develop infusion reaction after undergoing PEGylated uricase therapy, said method comprising the steps of: determining uric acid levels in a biological sample obtained from said patient at least 2 hours after administration of PEGylated uricase, wherein maintenance of a uric acid level at less than 4mg/dl indicates said uric acid level is associated with a lower likelihood of infusion reaction or wherein a uric acid level of at least 4mg/dl in said determined uric acid level indicates a higher likelihood of infusion reaction at a time point, when the uric acid level is measured. Further disclosed is a method to predict whether a patient will develop antibody-mediated PEGylated uricase clearance after being treated with PEGylated uricase without measuring anti-PEGylated uricase and anti-PEG antibodies titer, comprising the steps of: determining uric acid levels in a biological sample obtained from said patient at least 2 hours after administration of PEGylated uricase, wherein maintenance of a level at less than 4mg/dl indicates that uric acid level is associated with a lower likelihood of antibody-mediated PEGylated uricase clearance or wherein a uric acid level of at least 4mg/dl indicates that said determined uric acid level is associated with a higher likelihood of antibody-mediated PEGylated uricase clearance at a time point when said uric acid level is measured.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充